LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Kodu・Aktsiate loetelu・Savara Inc

Savara Inc

Suletud

SektorTervishoid

6.36 0.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.11

Max

6.39

Põhinäitajad
By Trading Economics
Sissetulek	840K -30M
Aktsiakasum	-0.14
Kasumimarginaal	-10,677.941
Töötajad	59
EBITDA	841K -29M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+50.79% upside

Turustatistika
By TradingEconomics
Turukapital	383M 1.2B
Eelmine avamishind	5.57
Eelmine sulgemishind	6.36

Uudiste sentiment

By Acuity

39%

61%

129 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

2.76 / 2.84 Toetus ja vastupanu

Savara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Võrdlus sarnastega

Hinnamuutus

Savara Inc Prognoos

Hinnasiht

By TipRanks

50.79% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD 50.79%

Kõrge 11 USD

Madal 7 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Savara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Savara Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.76 / 2.84Toetus ja vastupanu

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

129 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.